Schrodinger, Inc. (SDGR) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. Welcome to Schrodinger's conference call to review fourth quarter and full year 2024 financial results. My name is Kelvin and I'll be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, simply press pound key or star two. Please be advised that today's call is being recorded at the company's request. Now I would like to introduce your host for today's conference, Ms. Jared Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead. Thank you and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our fourth quarter and full year 2024 financial results. Earlier today, we issued the press release summarizing our financial results and progress across the company, which is available on our website at Schrodinger.com. Here with me on our call today are Rami Fareed, Chief Executive Officer. Jeff Porges, Chief Financial Officer, and Karen Nakansanya, President of R&D Therapeutics. Following our prepared remarks, we'll open the call for Q&A. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to our outlook for the full year 2025, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of initiation of and ...